Free Trial
→ The Crypto Secret Wall Street Doesn’t Want You to Know (From Crypto 101 Media) (Ad)

Cybin Q4 2024 Earnings Report

Cybin logo
$10.55 +0.55 (+5.50%)
(As of 12/3/2024 ET)

Cybin Earnings Headlines

Optimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market Potential
November 19, 2024 | markets.businessinsider.com
Cybin’s CYB003: Promising Clinical Trial Results Lead to Buy Rating
November 19, 2024 | markets.businessinsider.com
Lock in this disruptor’s share price before 12/5
Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads. This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years.
December 4, 2024 | Pacaso (Ad)
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
November 18, 2024 | theglobeandmail.com
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish
November 18, 2024 | msn.com
Cybin’s CYB003: Promising Efficacy in MDD and Strong Buy Rating Reaffirmed
November 18, 2024 | markets.businessinsider.com
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

View Cybin Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles